Compounds > midazolam

midazolam and aprepitant

midazolam has been researched along with aprepitant in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (55.56)	29.6817
2010's	4 (44.44)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andricopulo, AD; Moda, TL; Montanari, CA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Blum, RA; Constanzer, M; Dru, J; Goldberg, MR; Gottesdiener, KM; Hesney, M; Lines, CR; Majumdar, AK; McCrea, JB; Murphy, G; Panebianco, DL; Petty, KJ	1
Blum, RA; Bradstreet, TE; Evans, JK; Gargano, C; Lee, Y; Majumdar, AK; Petty, KJ; Shadle, CR	1
Ahmed, T; Barlas, S; Constanzer, M; Dru, J; Frick, GS; Greenberg, HE; Kraft, WK; Majumdar, AK; McCrea, JB; Petty, KJ; Selverian, DV; Yan, KX	1
Braun, MP; Dean, D; Fedgchin, M; Gargano, C; Gottesdiener, KM; Greenberg, HE; Kraft, WK; Majumdar, A; Murphy, MG; Panebianco, D; Pequignot, E; Petty, KJ; Stoch, SA; Valentine, J	1
Caro, L; Jin, B; Marbury, TC; Murphy, G; Ngo, PL; Panebianco, D; Shadle, CR; Valentine, J	1

Reviews

1 review(s) available for midazolam and aprepitant

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

5 trial(s) available for midazolam and aprepitant

Article	Year
Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clinical pharmacology and therapeutics, 2003, Volume: 74, Issue:2 Topics: Adult; Anti-Anxiety Agents; Antiemetics; Aprepitant; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Half-Life; Humans; Male; Midazolam; Morpholines; Neurokinin-1 Receptor Antagonists	2003
Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. Journal of clinical pharmacology, 2004, Volume: 44, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Aprepitant; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Enzyme Induction; Female; Half-Life; Humans; Injections, Intravenous; Male; Midazolam; Morpholines; Neurokinin-1 Receptor Antagonists; Tolbutamide	2004
Effect of aprepitant on the pharmacokinetics of intravenous midazolam. Journal of clinical pharmacology, 2007, Volume: 47, Issue:6 Topics: Adult; Antiemetics; Aprepitant; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Half-Life; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Midazolam; Morpholines	2007
Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6 Topics: Adult; Antiemetics; Aprepitant; Cross-Over Studies; Cytochrome P-450 CYP3A; Dexamethasone; Double-Blind Method; Drug Interactions; Female; Humans; Male; Midazolam; Morpholines; Ondansetron	2011
Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. Journal of clinical pharmacology, 2011, Volume: 51, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Aprepitant; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Injections, Intravenous; Male; Midazolam; Morpholines; Neurokinin-1 Receptor Antagonists; Young Adult	2011

Other Studies

3 other study(ies) available for midazolam and aprepitant

Article	Year
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013